Evidence Library

54 sources, 137 claims. Every source has a page showing what this platform has drawn from it, where that appears, and when its status was last checked with the publisher. 31 of 54 sources have been read.

By tier

The source hierarchy. Lower tiers are used only where higher tiers are silent.

Tier 1 — UK official — 23 sources
Tier 2 — Specialist societies — 26 sources
Tier 3 — Systematic evidence — 2 sources
Tier 4 — Primary research — 1 sources
Tier 5 — Reference organisations — 2 sources

By kind

By domain

A source appears in a domain if any claim citing it carries that domain. Sources appear in more than one.

Core hepatology — 91 claims
Critical care — 42 claims
Oncology and HCC — 18 claims
HPB surgery — 13 claims
Translational — 11 claims
Transplantation — 9 claims
Gene and RNA therapeutics — 8 claims

By status — the guideline atlas

What the publisher says, and when this platform last checked. A status is never inferred from a document's age.

By year of publication

The oldest source this platform relies on was published in 2009; the newest in 2026. Age is not a status: an older document may be perfectly current, and the status column says which.

2026 — 6 sources: NHS Blood and Transplant, NHS Blood and Transplant, NHS, NHS inform (NHS Scotland), Cochrane Hepato-Biliary Group, CSL Behring GmbH, via the electronic Medicines Compendium
2025 — 10 sources: European Association for the Study of the Liver, European Association for the Study of the Liver, European Association for the Study of the Liver, European Association for the Study of the Liver, European Association for the Study of the Liver, European Association for the Study of the Liver, European Association for the Study of the Liver and European Reference Network, British Society of Gastroenterology, British Association for the Study of the Liver and Society for Acute Medicine, NHS, British Society of Gastroenterology, British Association for the Study of the Liver and Society for Acute Medicine
2024 — 8 sources: European Association for the Study of the Liver, EASL, EASD and EASO (joint), American Association for the Study of Liver Diseases, American Association for the Study of Liver Diseases, British Society of Gastroenterology, NHS Tayside, Oxford University Hospitals NHS Foundation Trust, National Institute for Health and Care Excellence
2023 — 5 sources: European Association for the Study of the Liver, European Association for the Study of the Liver, American College of Gastroenterology, Medicines and Healthcare products Regulatory Agency, NHS
2022 — 3 sources: European Association for the Study of the Liver, Baveno VII Faculty, National Institute for Health and Care Excellence
2021 — 2 sources: British Society of Gastroenterology and British Association for the Study of the Liver, National Institute for Health and Care Excellence
2018 — 2 sources: European Association for the Study of the Liver, European Association for the Study of the Liver
2017 — 3 sources: European Association for the Study of the Liver, National Institute for Health and Care Excellence, NHS England
2016 — 3 sources: European Association for the Study of the Liver, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence
2015 — 1 source: Medicines and Healthcare products Regulatory Agency / GOV.UK
2014 — 2 sources: AASLD and EASL (joint), Medicines and Healthcare products Regulatory Agency / GOV.UK Drug Safety Update
2013 — 1 source: National Institute for Health and Care Excellence
2012 — 2 sources: National Institute for Health and Care Excellence, UK Statutory Instruments, via legislation.gov.uk
2011 — 2 sources: International Study Group of Liver Surgery, Barber K, Madden S, Allen J, et al.
2010 — 2 sources: European Association for the Study of the Liver, National Institute for Health and Care Excellence
2009 — 1 source: National Institute for Health and Care Excellence

What cannot be explored here, and why

The Definition of Done for this phase asks for exploration by trial and by translational topic as well. This platform holds no trial records at all — no trial registrations, no trial results, no registry identifiers — so a trial facet would be an empty page with a promising name. Translational material is explorable through the domain facets above rather than as a separate axis, because the eleven translational claims are all already reachable there.

There is no free-text search of the evidence, and no filter that combines two facets at once. The local search enhancement filters topic names and reading depths only; it does not search the evidence catalogue or combine its facets.